The reduced anticoagulant effect of fondaparinux at low antithrombin levels. 2009

Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
I. Department of Medicine, University Medical Centre Mannheim, Mannheim, Germany. carl-erik.dempfle@umm.de

BACKGROUND Low antithrombin levels may compromise the anticoagulant effect of heparin and heparin-related compounds, such as fondaparinux. METHODS We compared the anticoagulant effect of 10 concentrations of fondaparinux added to plasma samples with normal range (n = 25, antithrombin 95.4% +/- 9.2%) and low antithrombin (n = 22, antithrombin 45.5% +/- 13.2%) levels, using the Heptest coagulation assay. RESULTS Heptest clotting time was shorter at any given fondaparinux concentration in the antithrombin-deficient samples, indicating less anticoagulant effect than in the group with normal antithrombin levels. At a high fondaparinux concentration, a saturation effect is observed with no further increase in Heptest clotting time. Addition of antithrombin concentrates results in a shift of the dose-response curve. When antithrombin concentrate was added, Heptest clotting time increased up to a fondaparinux concentration of 10 microg/mL. CONCLUSIONS In the conventional prophylactic and therapeutic dose range, not only treatment with antithrombin concentrates but also an increase in fondaparinux dose normalizes the anticoagulant effect. A saturation effect is observed at high fondaparinux concentrations. Higher levels of antithrombin lead to an exaggerated effect of fondaparinux on Heptest.

UI MeSH Term Description Entries
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077425 Fondaparinux Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Arixtra,Fondaparinux Sodium,Quixidar
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct

Related Publications

Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
August 1982, Journal of the American Medical Women's Association (1972),
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
April 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
June 2013, Journal of thrombosis and haemostasis : JTH,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
April 2019, Laboratory medicine,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
May 2002, The Medical letter on drugs and therapeutics,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
October 2002, International journal of clinical practice,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
May 2014, ChemMedChem,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
February 1990, Thrombosis research,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
January 1929, The Biochemical journal,
Carl-Erik Dempfle, and Julia Eichner, and Nenad Suvajac, and Parviz Ahmad-Nejad, and Michael Neumaier, and Martin Borggrefe
April 1973, Acta medica Scandinavica,
Copied contents to your clipboard!